Image pharmaphorum Editor News Hu-manity.co blockchain initiative helps people claim rights... Initiative helps people safeguard personal information News Crescendo hires ex-Roche R&D guru to develop T-cell technolo... Biotech has already raised $70m this year in second funding round News UK gene and cell therapy manufacturing hub clears regulatory... The UK's regulator has granted new licences to a hub of biotech companies to allow them to continue manufacturing of groundbreaking gene and cell therapies at an innovative purpose-built ce News FDA rejects GSK's Nucala in COPD, asking for more clinical d... Blow to GSK's hopes for a new indication Load more results
News Hu-manity.co blockchain initiative helps people claim rights... Initiative helps people safeguard personal information
News Crescendo hires ex-Roche R&D guru to develop T-cell technolo... Biotech has already raised $70m this year in second funding round
News UK gene and cell therapy manufacturing hub clears regulatory... The UK's regulator has granted new licences to a hub of biotech companies to allow them to continue manufacturing of groundbreaking gene and cell therapies at an innovative purpose-built ce
News FDA rejects GSK's Nucala in COPD, asking for more clinical d... Blow to GSK's hopes for a new indication
News EU clears first drug therapy for rare disease cALD Neuraxpharm and Minoryx' Nezglyal has become the first approved drug therapy in the EU for rare neurodegenerative disease cALD.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
